Cargando…
Identification of a c-MYB-directed therapeutic for acute myeloid leukemia
A significant proportion of patients suffering from acute myeloid leukemia (AML) cannot be cured by conventional chemotherapy, relapsed disease being a common problem. Molecular targeting of essential oncogenic mediators is an attractive approach to improving outcomes for this disease. The hematopoi...
Autores principales: | Clesham, Katherine, Walf-Vorderwülbecke, Vanessa, Gasparoli, Luca, Virely, Clemence, Cantilena, Sandra, Tsakaneli, Alexia, Inglott, Sarah, Adams, Stuart, Samarasinghe, Sujith, Bartram, Jack, Williams, Gareth, de Boer, Jasper, Williams, Owen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162920/ https://www.ncbi.nlm.nih.gov/pubmed/35368048 http://dx.doi.org/10.1038/s41375-022-01554-9 |
Ejemplares similares
-
ARHGEF4 Regulates an Essential Oncogenic Program in t(12;21)-Associated Acute Lymphoblastic Leukemia
por: Virely, Clemence, et al.
Publicado: (2020) -
The AAA+ ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia
por: Armenteros-Monterroso, Elena, et al.
Publicado: (2019) -
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021) -
Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias
por: Cantilena, Sandra, et al.
Publicado: (2022) -
ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma
por: Andersson, Mattias K., et al.
Publicado: (2020)